Strategic acquisitions Fortis Life Sciences has a history of acquiring complementary companies such as Azcentral and International Point of Care, expanding its portfolio and market reach in the point-of-care testing and diagnostics sectors. This strategic growth indicates potential collaboration opportunities to integrate antibody and biosensing technologies.

Innovative product launches The recent launch of enhanced lateral flow assay kits utilizing gold nanoparticles with significantly increased sensitivity demonstrates Fortis’ commitment to advancing diagnostic technology, creating opportunities to supply advanced reagents, materials, and custom solutions for their testing platforms.

Global expansion Fortis has expanded its presence internationally with new offices in Seoul, South Korea, and appointing leadership in the Asia-Pacific region. This regional growth offers sales prospects for reagents, antibodies, and bioprocessing tools tailored to the Asia market.

Research collaborations Partnership with Astraea Bio to enhance spatial biology and multi-omics research highlights opportunities to provide specialized reagents, antibodies, and research tools that support cutting-edge scientific initiatives and collaborative projects.

Recent antibody focus Following its acquisition of Abcore, Fortis is positioned to leverage antibody discovery and nanobody technologies, indicating a market need for custom antibodies, immunoassay reagents, and bioprocessing products to serve biopharma clients engaged in therapeutic development.